The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
REACT: A phase II study of rindopepimut (CDX-110) plus bevacizumab (BV) in relapsed glioblastoma (GB).
David A. Reardon
Research Funding - Celldex
James J. Vredenburgh
Consultant or Advisory Role - Roche/Genentech
Honoraria - Roche/Genentech
Research Funding - Celldex
Annick Desjardins
No relevant relationships to disclose
Ronald G. Steis
Research Funding - Celldex
Erin M. Dunbar
Honoraria - FLA Hosp
Research Funding - Celldex
Nitin B. Chandramouli
Research Funding - Celldex
Olivier Rixe
Research Funding - Celgene
Jennifer A Green
Employment or Leadership Position - Celldex
Stock Ownership - Celldex
Thomas A. Davis
Employment or Leadership Position - Celldex
Stock Ownership - Celldex
John Howard Sampson
Consultant or Advisory Role - Celldex
Stock Ownership - Celldex
Honoraria - Celldex
Research Funding - Celldex